The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein Vimentin
Open accessAbstract
The natural product withaferin A (WFA) exhibits antitumor and antiangiogenesis activity in vivo, which results from this drug's potent growth inhibitory activities. Here, we show that WFA binds to the intermediate filament (IF) protein, vimentin, by covalently modifying its cysteine residue, which is present in the highly conserved alpha-helical coiled coil 2B domain. WFA induces vimentin filaments to aggregate in vitro, an activity manifested in vivo as punctate cytoplasmic aggregates that colocalize vimentin and F-actin. WFA's potent dominant-negative effect on F-actin requires vimentin expression and induces apoptosis. Finally, we show that WFA-induced inhibition of capillary growth in a mouse model of corneal neovascularization is compromised in vimentin-deficient mice. These findings identify WFA as a chemical genetic probe of IF functions, and illuminate a potential molecular target for withanolide-based therapeutics for treating angioproliferative and malignant diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review.
Mishra, L. C., Singh, B. B., & Dagenais, S. (2000) · PubMed · Cited by 1,174
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10403 · Cited by 920
Self-citationSin, N., Meng, L., Wang, M. Q. W., Wen, J. J., Bornmann, W. G., & Crews, C. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6099 · Cited by 635
Mice lacking vimentin develop and reproduce without an obvious phenotype
Colucci-Guyon, E., Portier, M.-M., Dunia, I., Paulin, D., Pournin, S., & Babinet, C. (1994) · Cell · doi:10.1016/0092-8674(94)90553-3 · Cited by 598
Vimentin is secreted by activated macrophages
Mor-Vaknin, N., Punturieri, A., Sitwala, K., & Markovitz, D. M. (2003) · Nature Cell Biology · doi:10.1038/ncb898 · Cited by 522
Self-citationGriffith, E. C., Su, Z., Turk, B. E., Chen, S., Chang, Y.-H., Wu, Z., Biemann, K., & Liu, J. O. (1997) · Chemistry & Biology · doi:10.1016/s1074-5521(97)90198-8 · Cited by 421
Self-citationChemical genetics resulting from a passion for synthetic organic chemistry
Schreiber, S. L. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00126-6 · Cited by 410
Impaired wound healing in embryonic and adult mice lacking vimentin
Eckes, B., Guyon, E. C., Smola, H., Nodder, S., Babinet, C., Krieg, T., & Martin, P. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.13.2455 · Cited by 398
Withaferin A is a potent inhibitor of angiogenesis
Mohan, R., Hammers, H., Bargagna-mohan, P., Zhan, X., Herbstritt, C., Ruiz, A., Zhang, L., Hanson, A., Conner, B., Rougas, J., et al. (2004) · Angiogenesis · doi:10.1007/s10456-004-1026-3 · Cited by 382
Self-citationPlakins: a family of versatile cytolinker proteins
Leung, C. L., Green, K. J., & Liem, R. K. H. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02180-8 · Cited by 314
Strelkov, S. V., Herrmann, H., Geisler, N., Wedig, T., Zimbelmann, R., Aebi, U., & Burkhard, P. (2002) · The EMBO Journal · doi:10.1093/emboj/21.6.1255 · Cited by 294
van Beijnum, J. R., Dings, R. P., van der Linden, E., Zwaans, B. M. M., Ramaekers, F. C. S., Mayo, K. H., & Griffioen, A. W. (2006) · Blood · doi:10.1182/blood-2006-02-004291 · Cited by 244
Yang, H., Shi, G., & Dou, Q. P. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.030015 · Cited by 226
Soellner, P., Quinlan, R. A., & Franke, W. W. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7929 · Cited by 214
A Direct Interaction between Actin and Vimentin Filaments Mediated by the Tail Domain of Vimentin
Esue, O., Carson, A. A., Tseng, Y., & Wirtz, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605452200 · Cited by 192
Bär, H., Strelkov, S. V., Sjöberg, G., Aebi, U., & Herrmann, H. (2004) · Journal of Structural Biology · doi:10.1016/j.jsb.2004.04.003 · Cited by 189
Lundkvist, A., Reichenbach, A., Betsholtz, C., Carmeliet, P., Wolburg, H., & Pekny, M. (2004) · Journal of Cell Science · doi:10.1242/jcs.01221 · Cited by 161
Impairment of the ubiquitin‐proteasome system in desminopathy mouse hearts
Liu, J., Chen, Q., Huang, W., Horak, K. M., Zheng, H., Mestril, R., & Wang, X. (2005) · The FASEB Journal · doi:10.1096/fj.05-4869fje · Cited by 155
Self-citationSingh, S., Sadacharan, S. K., Su, S., Belldegrun, A. S., Persad, S., & Singh, G. K. J. (2003) · PubMed · Cited by 154
The Intermediate Filament Protein Vimentin Is a New Target for Epigallocatechin Gallate
Ermakova, S. P., Choi, B. Y., Choi, H. S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414185200 · Cited by 145
Actin microfilament aggregation induced by withaferin A is mediated by annexin II
Falsey, R. R., Marron, M. T., Gunaherath, G. M. K. B., et al. (2005) · Nature Chemical Biology · doi:10.1038/nchembio755 · Cited by 143
Activity-Based Protein Profiling
Berger, A. B., Vitorino, P. M., & Bogyo, M. S. (2004) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200404060-00004 · Cited by 142
Kim, K. B., Myung, J., Sin, N., & Crews, C. M. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00612-5 · Cited by 116
Self-citationChemical genetics: exploring and controlling cellular processes with chemical probes
Crews, C. M., & Splittgerber, U. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01425-5 · Cited by 116
Endothelial signalling events during leukocyte transmigration
Hordijk, P. L. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05440.x · Cited by 110
Terzi, F., Henrion, D., Colucci‐Guyon, E., Fédérici, P., Babinet, C., Levy, B. I., Briand, P., & Friedlander, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119675 · Cited by 93
A Chemical and Genetic Approach to the Mode of Action of Fumagillin
Zhang, Y., Yeh, J.-R. J., Mara, A., Ju, R., Hines, J. F., Cirone, P., Griesbach, H. L., Schneider, I., Slusarski, D. C., Holley, S. A., et al. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.07.010 · Cited by 91
Hamza, A., & Zhan, C. (2006) · The Journal of Physical Chemistry B · doi:10.1021/jp0550762 · Cited by 73
Self-citationDevelopment of withaferin A analogs as probes of angiogenesis
Yokota, Y., Bargagna‐Mohan, P., Ravindranath, P. P., Kim, K. B., & Mohan, R. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.039 · Cited by 68
Self-citationSustained Inhibition of Corneal Neovascularization by Genetic Ablation of CCR5
Ambati, B. K., Anand, A., Joussen, A. M., Kuziel, W. A., Adamis, A. P., & Ambati, J. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0685 · Cited by 67
Tetracycline regulated expression of vimentin in fibroblasts derived from vimentin null mice
Holwell, T. A., Schweitzer, S. C., & Evans, R. M. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.16.1947 · Cited by 64
Self-citationBargagna‐Mohan, P., Ravindranath, P. P., & Mohan, R. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1452 · Cited by 57
Self-citationFuska, J., Fusková, A., Rosazza, J. P. N., et al. (1984) · PubMed · Cited by 51
In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development
Phung, M. W., & Dass, C. R. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.2.0001 · Cited by 19
Cited by
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Vimentin in cancer and its potential as a molecular target for cancer therapy
Satelli, A., & Li, S. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0735-1 · Cited by 1,557
Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker
Yang, Z., & Wang, K. K. W. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.04.003 · Cited by 1,050
Huang, J.-F., Guo, Y.-J., Zhao, C.-X., Yuan, S.-X., Wang, Y., Tang, G.-N., Zhou, W.-P., & Sun, S.-H. (2013) · Hepatology · doi:10.1002/hep.26195 · Cited by 323
Withaferin A targets heat shock protein 90 in pancreatic cancer cells
Yu, Y., Hamza, A., Zhang, T., Gu, M., Zou, P., Newman, B., Li, Y., Gunatilaka, A. A. L., Zhan, C.-G., & Sun, D. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.017 · Cited by 316
Self-citation
Metadata
- Authors
- Bargagna-Mohan, P., Hamza, A., Kim, Y.-E., Khuan (Abby) Ho, Y., Mor-Vaknin, N., Wendschlag, N., Liu, J., Evans, R. M., Markovitz, D. M., Zhan, C.-G., Kim, K. B., & Mohan, R.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2007-06
- Volume
- 14
- Issue
- 6
- Pages
- 623-634
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2070777173
- Cited by
- 348
- References
- 35
- FWCI
- 23.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.